Context Therapeutics Inc.
AI Valuation
AI-generated fair value estimate for this company.
AI Fair Value
$0.47
Market Price
$0.32
Undervalued By
31.9%
Method: Net cash NAV: $43.0M cash (6/30/26, no material debt disclosed), divided by 91.88M shares outstanding.
Reasoning: Context Therapeutics is a pre-revenue Phase 1 oncology biotech (CTIM-76, FDA Fast Track) with topline data not expected until 2027; without a disclosed peak-sales estimate a DCF would be an ungrounded guess, so the company's real, reported cash balance is used as the defensible floor value.